# A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer

> **NCT02283320** · PHASE2 · COMPLETED · sponsor: **BIND Therapeutics** · enrollment: 69 (actual)

## Conditions studied

- KRAS Positive Patients With Non-small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer

## Interventions

- **DRUG:** BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)

## Key facts

- **NCT ID:** NCT02283320
- **Lead sponsor:** BIND Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2016-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02283320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02283320, "A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02283320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*